anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed research will provide important insight into two serious problems for veterans' healthcare: 1) mixed effectiveness of communication improvement interventions in the VA to date, and 2) persistence of racial/ethnic disparities in VA healthcare. We have identified 4 "best acts" of physician communication that patients believe to be most important in a clinical interaction. We propose to develop and evaluate a physician communication intervention that focuses specifically on these acts. In addition, our abundance of pilot study data from patients of various races/ethnicities enables us to create an intervention applicable to communication that spans patient race/ethnicity. Evaluating this intervention with physicians and patients in 2 independent VA primary care settings will help determine whether a patient-driven communication focus that incorporates input from patients of varied race/ethnicity can help "close the gap" in health outcomes between white and minority veterans.

We aim to (1) demonstrate the efficacy of using "best acts" of physician communication as content for an intervention to improve physician communication skills overall and reduce variation in communication with white versus racial/ethnic minority patients, and (2) assess the impact of patient experiences of "best acts" on patients' perceptual and behavioral outcomes.

We have collected data from over 200 primary care patients as they viewed a video of themselves and their physician interacting during a clinic visit. From these data, we are developing an educational intervention for physicians that focuses specifically on the 4 "best acts" we have identified. Scripts of the 4 "best acts" will be developed, and standardized patients at Baylor College of Medicine will perform the acts, which will be video recorded. We will then conduct a 2-site longitudinal observational study of 16 primary care physicians (8 at each site) and 36 patients of each physician. At the first site at 3-month intervals, physicians will attend an instruction session consisting of viewing a video of one best act and participating in group discussion, role-playing re-enactment of the act, and formulation of bulleted "take-away" points to facilitate subsequent recall. Once completed, the sequence of sessions will occur at the second site. At both sites, clinical interactions of participating physicians and patients will be audio recorded, and audio recordings will be analyzed for frequency of occurrence of the 4 "best acts." After each study visit, each patient will complete validated surveys measuring patients' perceptions of their physician on 4 affective dimensions known to impact patients' subsequent perceptual and behavioral outcomes. Efficacy will be assessed across patient demographics.
The present invention provides a polyethylene glycol derivative comprising a repeat unit having the structure of Formula (I) and a terminal group having the structure of Formula (II). The polyethylene glycol derivative provided by the present invention has good biocompatibility, due to the repeat unit having the structure of Formula (I); and can react with various groups such as amino, (acyl)hydrazino, and aminooxy with a fast reaction rate under mild reaction conditions, due to the o-phthalaldehyde terminal group having the structure of Formula (II). The polyethylene glycol derivative provided by the present invention is mixed with polyethylene glycol having an amino-containing terminal group in an aqueous medium, to rapidly form a chemically cross-linked hydrogel material. The hydrogel material has mild preparation conditions, fast gel-forming speed, high mechanical strength, and good stability. This polyethylene glycol hydrogel can be applied as drug sustained-release carrier, tissue engineering scaffold, etc. in the field of biomedical materials.
Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
The study will be a Smartphone-based interventional trial. To assess the effectiveness of the intervention weight- and eating-related behavior and cognitive and emotional responding as well as body-weight will be assessed using questionnaires and ecological momentary assessment (EMA) for one week at a pre- (T0), post- (T1) and two follow-up-assessments after six (T2) and 12 months (T3).
The present invention relates to a tablet of ganoderma lucidum and spirulina and a preparation method thereof. 87 to 92.5% of spirulina fine powder and 5 to 8% of ganoderma lucidum spore powder with broken walls are used as principal raw material, and 1.0 to 2.0% of cellulose, 1.25 to 2.5% of silicon dioxide and 0.25 to 0.5% of magnesium stearate are matched. After the material is sufficiently mixed and sieved by a sieve of 60 meshes, dry powder is directly pressed into the tablet by a ZP19 rotary tablet machine with a molding method. The product of the present invention not only maintains spirulina nutrients, but also supplements the biological active components of the ganoderma lucidum spore powder with broken walls. The product is rich in more than 55% of rich good protein, eight requisite amino acids for human bodies, various vitamins, gamma-linolenic acids, beta-carotenes whose quantity is 10 times of that of carrots, nutrient components(polysaccharide, etc.) and biological active components. The tablet can supplement and balance nutrients, and obviously enhance body immunity. The tablet is an ideal nutrient health-care food for people with cancer and people who have weak bodies.
The invention belongs to the technical field of mask materials, and particularly discloses a nanofiber mask with a slow-release effect, and a preparation method and application thereof. The nanofiber mask with the slow release effect is prepared from the following components in parts by mass: 0-50 parts of PVA 178810-50 parts, 0-98 parts of PVA17995 and 1-15 parts of active substance. Different from the traditional preparation idea of the facial mask, the active ingredients are directly mixed with PVA1799 and PVA1788 to prepare spinning solution, and the nano-fiber facial mask with the slow-release effect is directly prepared by electrostatic spinning. The application method comprises moistening face, spreading dry facial mask, applying to face, and spraying appropriate amount of water. Active substances can be continuously released into the solution in the using process, the face of a user is always soaked in the nutrient solution with certain concentration, the situation that the nutrient solution is too high in concentration and absorbs water from the face is avoided, certain concentration can be guaranteed, and the active substances are continuously supplemented to the skin. Ensuring the use effect.
The invention provides a lignin-verteporfin self-assembled nano-composite and preparation and application thereof. The nano-composite is composed of amphiphilic high polymer lignin and hydrophobic drug micromolecular verteporfin. Lignin and verteporfin spontaneously assemble to form micelle nano-composites, and then ionic liquid with permeability is prepared through salt decomposition reaction, so that the novel percutaneous delivery system ILs-LVNs is finally formed. LVNs not only has the function of scavenging active oxygen, but also can activate Wnt channel by up-regulating Trps1 transcription factor signal, accelerate wound regeneration, and block abnormal proliferation of fibroblast by inhibiting YAP gene expression, thereby reducing scar formation. The percutaneous delivery system ILs-LVNs provided by the invention has double functions, and can promote wound healing and inhibit scar formation. The innovative delivery strategy of the present invention provides a highly effective, low side effect method for chronic wound and hypertrophic scar treatment.
A system and a process for automatic detection of medical adherence in a medical device is disclosed. The process includes automatically detecting a state change of a medical device based on a motion of the medical device. The state change may be from a closed state to an open state. It is determined whether a state change processor is within a range of the medical device. The state change processor monitors medical or medicine adherence. Upon determining that the state change processor is within the range of the medical device, state change information is sent to the state change processor. A real time change data when the medical activity detector and the state change detector are within a communication range is stored.
The control group will receive "usual care" - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted "social" query (e.g. "How are things going for you?"). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points.
BACKGROUND: The aim of this study was to identify the risk factors for postoperative delirium (POD) in elderly patients undergoing heart valve surgery with cardiopulmonary bypass (CPB).
METHODS: Elderly patients undergoing elective heart valve surgery with CPB in The First Affiliated Hospital of Wenzhou Medical University between March 2022 and March 2023 were selected for this investigation. They were divided into a POD group and a non-POD group. Their baseline information was collected and recorded, and the patients were subjected to neurocognitive function assessment using the Mini-Mental State Examination and the Montreal Cognitive Assessment scales before surgery. We also recorded their intraoperative indicators such as duration of surgery, duration of CPB, duration of aortic cross-clamp, blood transfusion, and postoperative indicators such as duration of mechanical ventilation, postoperative 24-hour drainage volume, and pain score. Regional cerebral oxygen saturation was monitored intraoperatively by near-infrared spectroscopy based INVOS5100C Regional Oximeter. Patients were assessed for the occurrence of POD using Confusion Assessment Method for the Intensive Care Unit, and logistic regression analysis of risk factors for POD was performed.
RESULTS: The study finally included 132 patients, with 47 patients in the POD group and 85 ones in the non-POD group. There were no significant differences in baseline information and preoperative indicators between the two groups. However, marked differences were identified in duration of surgery, duration of CPB, duration of aortic cross-clamp, duration of postoperative mechanical ventilation, postoperative length of stay in cardiac intensive care unit, postoperative length of hospital stay, intraoperative blood transfusion, postoperative pain score, and postoperative 24-hour drainage volume between the two groups (p < 0.05). Additionally, the two groups had significant differences in rScO2 at each intraoperative time point and in the difference of rScO2 from baseline at each intraoperative time point (p < 0.05). Multivariate logistic regression analysis showed that duration of surgery > 285 min (OR, 1.021 [95% CI, 1.008-1.035]; p = 0.002), duration of postoperative mechanical ventilation > 23.5 h (OR, 6.210 [95% CI, 1.619-23.815]; p = 0.008), and postoperative CCU stay > 3.5 d (OR, 3.927 [95% CI, 1.046-14.735]; p = 0.043) were independent risk factors of the occurrence of POD while change of rScO2 at T1>50.5 (OR, 0.832 [95% CI 0.736-0.941]; p = 0.003) was a protective factor for POD.
CONCLUSION: Duration of surgery duration of postoperative mechanical ventilation and postoperative CCU stay are risk factors for POD while change of rScO2 at T1 is a protective factor for POD in elderly patients undergoing heart valve surgery with CPB.
Participants assigned to Arm A will engage in CICADAS app only for the first 16 weeks of the intervention period. After the completion of the first intervention period and the mid-intervention assessment (V3) visit, these participants will then be assigned to the PEERS only group for the second 16 weeks of the intervention period. Participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician.
Lay summary:

About one in six hospital inpatients suffer Acute Kidney Injury (AKI), also called acute renal failure. About a third of patients with AKI die. The large majority of patients with AKI are managed by doctors who are not kidney experts. Effective AKI advice and treatments are available but not currently integrated into routine care. A recent National review of the care of patients who died from AKI showed poor management of many patients. Early diagnosis of AKI can avoid complications, dialysis (which affects the quality of life of patients, and is costly) or death. AKI is diagnosed by a change in a blood test. We have developed computer software to diagnose AKI earlier. It sends a warning or 'Alert' about the test to our team of kidney experts. We will further develop the settings of the Alert system. It needs to send an Alert for the right patients. We will also study the best way to make clinicians pay attention to their patients who are developing AKI. When our expert Outreach team receive an Alert, they will call the doctor or nurse looking after the patient with AKI. We will advise on the best treatment for that patient, to reduce their risk of death, dialysis and other complications. We will do a pilot study in one large hospital, to further develop the system, and check it reduces the risk of death or complications from AKI. We will use this work to develop a larger trial of this new system of care for patients with AKI in different hospitals. This will convince the wider NHS of the need to change, and show how to prevent or reduce AKI. Ultimately we aim to improve patients' lives by reducing avoidable death and illness from AKI , and also save the NHS money.
A curative for rheumatism and other complaints is produced by culturing in solid or in liquid media fluorescent microbes isolated from sea animals, e.g. cuttle fish, or fresh water animals, or sea water, extracting the active substance with distilled water containing or not antiseptics, e.g. phenol, or with an organic solvent, e.g. methanol, ethanol, butanol, benzene, or aqueous solutions thereof, or with physiological salt solution or with acid or alkali solutions, separating protein and lipoid material when present, and recovering the active substance, including a final stage of evaporating to dryness in vacuum at low temperature.  When extraction is effected by non-organic solvents, protein, amino acids and lipoid material are separated by filtration through asbestos treated with sodium silicate and magnesium silicate.  After filtration, the pH is adjusted to 2-6, the active substance is adsorbed on, say kaolin or active carbon and the adsorbate treated, e.g. with caustic soda solution at pH 8-12 to elute the active substance.  After concentration, alcohol is added to precipitate substances insoluble therein, and the filtrate is dried in vacuum at low temperature.  As an alternative to the adsorbtion procedure, silver nitrate, lead acetate, &c. is added to precipitate a heavy metal salt of the active substance, which is recovered by precipitating the metal with hydrogen sulphide.  The filtrate is concentrated to dryness and the active substance dissolved in carbolic acid, alcohols, acetone, benzene, or aqueous solutions thereof.  The culture medium may be dried at low temperature and lipoid extracted with ether prior to extraction of the active substance.  Prior to or during extraction, the microbe may be destroyed by physical means, e.g. by heat or pressing, or by chemical means, using acid or alkali.
Abdominal surgery is a critical surgery, with more and more attention being paid to postoperative life quality and associated complications in recent years. Among these complications, postoperative gastrointestinal dysfunction is the most common complication of abdominal surgery. Acupuncture therapy is a treatment approach based on the Traditional Chinese Medicine theory, and its feasibility in aiding gastrointestinal recovery after abdominal surgery is supported by both Traditional Chinese Medicine theory and animal experiments. A lot of clinical research has been conducted to evaluate its efficacy, albeit with limitations, and at preliminary stages. Moreover, intervention timing, acupoint selection, and patient benefits should also be considered in clinical practices. This article summarizes the progress of clinical research on acupuncture therapy in gastrointestinal recovery after abdominal surgery and discusses related issues and operations, with the aim to provide new insights and prospects for the incorporation of acupuncture into the Enhanced Recovery After Surgery protocol.
A growing body of evidence demonstrates that older patients with cognitive impairment (CI) who are hospitalized for the management of their medical illnesses are especially vulnerable to hospital acquired complications such as falls, injuries, pressure ulcers, restraints, and delirium. These complications contribute to mortality, poorer functional status, limited rehabilitation, prolonged length of stay, increased institutionalization, and higher health care costs. Evidence suggests that interdisciplinary geriatric inpatient services improve care for hospitalized older adults without CI; however, their effectiveness among older adults with CI is less clear. One reason may be the ever-quickening pace of care in the hospital setting. Thus, matching geriatric evaluation and recommendations to the true pace of hospital care may be one mechanism to improve the care of older adults with CI.

A recent report from the Institute of Medicine suggested that integrating information technology (IT) into health care is the best route to improve the overall safety and quality of the health care system. The hypothesis of this study is that missed, delayed, post-hoc, and incomplete implementation of the geriatric service-based recommendations are significant factors explaining the poor outcomes among hospitalized older adults with cognitive impairment (CI). Wishard Memorial Hospital's physicians are already using a Computerized Decision Support System (CDSS), developed by the Regenstrief Institute, to guide their medical services. For this study, the content of this CDSS will be modified to the special needs of older adults with CI. A major advantage of such a system is reducing the time to implementation of geriatric recommendations with a specific focus on preventing the initiation of potentially harmful medications and procedures during the critical first 48 hours of hospitalization.

A total of 400 patients with cognitive impairment who have been hospitalized in a medical ward will be recruited for this study. Patients will be randomized to receive either standard care or the proactive screening program for CI combined with the modified CDSS. The electronic medical record for all patients will be reviewed for prescriptions for potentially inappropriate medications, urinary catheters, or physical restraints during the first 24 hours and the entire hospital stay. Medical records will be used to determine the total number of hospital acquired complications that may be related to CI; these include falls, injuries such as pulling out IV lines or urinary catheters, pressure ulcers, and new-onset delirium episodes that developed during hospitalization. Also, the time elapsed between screening for CI and the physician ordering a geriatric consultation will be calculated using the electronic medical record.
The present invention discloses an oxygen absorber composition in the form of an oxygen absorber tablet and a process for the preparation of the oxygen absorber tablet. The oxygen absorber tablet includes composition A and iron powder. Composition A has binding agent, carbon, silica gel, clay, hygroscopic salt, and magnesium stearate. The ratio of iron powder to Composition A is determined depending on the target air volume from where the oxygen is to be removed. The tablets are prepared for 30 cc, 100 cc, 250 cc and 500 cc of target air volume. The tablet has an enhanced oxygen absorption amount per unit volume. It absorbs moisture and odour from the available target air volume and helps diminish the hydrogen and carbon dioxide gas generated during oxidation. The tablets are compact, user friendly, increases shelf life of pharmaceutical, food and nutraceutical products.
Epidemiological evidence shows a potentially protective role for estrogen in women with schizophrenia. The onset of schizophrenia is later in woman than in men, with generally a less severe course until after the menopause, when for many women, reductions in estrogen levels appear to trigger an exacerbation or illness (Hafner 2003). ERα (Estrogen receptor alpha) expression is known to be reduced in schizophrenia (Wong, Woon et al. 2010). Raloxifene is a selective estrogen receptor modulator that acts as an estrogen antagonist in breast tissue and may have agonistic actions in the brain. Several studies (Kulkarni, Riedel et al. 2001; Chua, de Izquierdo et al. 2005; Kulkarni, Gurvich et al. 2010) indicate that treatment with estrogen and raloxifene improves symptoms in females with schizophrenia, and recently they showed an improvement in PANSS score in post menopausal women with schizophrenia receiving 60-120mg/d of raloxifene compared to placebo
The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.